Hemostats Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Thrombin-based Hemostats, Oxidized Regenerated Cellulose-based Hemostats, Combination Hemostats, Gelatin-based Hemostats, Collagen-based Hemostats, Other Hemostats), By Formulation (Matrix & Gel Hemostats, Sheet & Pad Hemostats, Sponge Hemostats, Powder Hemostats), By Application (Orthopedic Surgery, General Surgery, Neurological Surgery, Cardiovascular Surgery, Reconstructive Surgery, Gynecological Surgery, Other Surgical Applications) Region and Competition, 2020-2030F

Market Overview

The Global Hemostats Market, valued at USD 3.82 Billion in 2024, is projected to experience a CAGR of 7.48% to reach USD 5.89 Billion by 2030. Hemostats are specialized medical devices or agents employed to arrest bleeding during surgical procedures, traumatic injuries, or in various medical conditions by promoting coagulation or providing a mechanical barrier. The global hemostats market growth is principally driven by an escalating volume of surgical interventions worldwide, a progressively aging global population prone to various chronic diseases requiring surgical treatment, and the rising incidence of trauma cases. According to the International Society of Aesthetic Plastic Surgery (ISAPS), over 15.8 million aesthetic surgical procedures were performed globally in 2023, indicating a substantial demand for surgical consumables.

A significant challenge impeding market expansion is the stringent and complex regulatory approval processes for new hemostatic products. These rigorous requirements often lead to protracted development timelines and increased costs, potentially delaying the introduction of innovative solutions to address unmet clinical needs.

Key Market Drivers

The Global Hemostats Market is significantly influenced by the confluence of a growing geriatric population and continuous advancements in hemostatic technologies. The increasing proportion of older adults globally represents a substantial and expanding patient demographic requiring surgical intervention. This demographic often presents with multiple comorbidities, necessitating more frequent and complex procedures where effective bleeding control is paramount. For instance, according to a study highlighted by ResearchGate in August 2025, older individuals typically require surgical procedures four times more often than the younger population, directly increasing the demand for hemostatic agents during these interventions. This demographic shift not only increases the sheer volume of surgeries but also elevates the complexity, thereby driving the need for sophisticated hemostatic solutions.

Complementing this demographic push, advancements in hemostatic technologies and ongoing product innovation serve as another crucial market driver. Research and development efforts are focused on creating more efficacious, easier-to-use, and specialized hemostatic agents that improve patient safety and surgical outcomes. These innovations include novel material science applications and improved delivery systems designed for various surgical environments, including minimally invasive procedures. According to Medical Buyer, in June 2025, investments in hemostatic technology reached a record USD 487 million in 2023, underscoring the robust focus on developing next-generation solutions. Such innovation enhances the clinical utility and adoption of hemostats, contributing substantially to market expansion. The global hemostats market itself grew to USD 2,884.14 million in 2024, as reported by Medical Buyer in June 2025, reflecting the overall impact of these driving factors.

Download Free Sample Report

Key Market Challenges

The stringent and complex regulatory approval processes represent a significant impediment to the growth of the Global Hemostats Market. These rigorous requirements necessitate protracted development timelines and substantially increased costs for manufacturers. Such an environment diverts significant financial and human capital towards compliance rather than innovation, thereby slowing the introduction of novel hemostatic solutions to address unmet clinical needs.

According to MedTech Europe's 2024 IVDR & MDR Survey, certification and maintenance costs for medical devices have escalated by up to 100% or more compared to previous directives, significantly impacting manufacturers. Furthermore, the survey indicated that the choice of the European Union as the first launch geography for medical devices has dropped by 33% for large manufacturers and 19% for small and medium-sized enterprises since the application of the new regulations. This reluctance to introduce products initially in major markets, driven by the regulatory burden, directly restricts market expansion by delaying the availability of new and improved hemostats.

Key Market Trends

Two significant trends are currently shaping the Global Hemostats Market.

The expanding adoption of minimally invasive surgical approaches significantly influences the global hemostats market by creating demand for specialized bleeding control solutions. These techniques, favored for enhanced patient recovery and reduced hospital stays, are increasingly applied across diverse surgical disciplines. According to the National Institutes of Health, over 1 million hip and knee arthroplasty procedures were performed annually in the U. S. in 2024, a large volume where minimally invasive techniques are increasingly utilized. This procedural shift necessitates hemostatic agents that are effective and precisely applicable within constricted surgical fields. For example, Ethicon introduced its ETHIZIA Hemostatic Sealing Patch in November 2023, designed for adaptable handling in both open and minimally invasive surgeries.

A distinct trend influencing the hemostats market is the shift towards personalized hemostasis approaches, which involves tailoring bleeding management strategies to individual patient profiles. This paradigm recognizes that patient-specific factors, such as genetic predispositions and comorbidities, necessitate customized hemostatic interventions. According to the World Federation of Hemophilia, over 400,000 people lived with hemophilia worldwide in 2024. These individuals require highly personalized treatment plans for effective bleeding management, underscoring the demand for tailored hemostatic solutions. Companies are responding by focusing on advanced product development; CSL Limited, for instance, announced in February 2025 that it was focusing on developing personalized hemostasis therapies designed for patient-specific bleeding risks.

Segmental Insights

In the Global Hemostats Market, thrombin-based hemostats represent the fastest-growing segment, primarily driven by their crucial role in managing bleeding during diverse surgical interventions. The increasing volume of complex procedures, including cardiovascular and orthopedic surgeries, coupled with an expanding aging population, necessitates highly effective hemostatic solutions. Rapid advancements in recombinant thrombin technology have significantly enhanced product efficacy and safety, mitigating risks associated with animal-derived alternatives. This shift, alongside continuous research and development efforts, contributes to the segment's rapid growth by providing superior and safer options that quickly facilitate the clotting process, optimizing surgical outcomes.

Regional Insights

North America dominates the global hemostats market, primarily driven by its advanced healthcare infrastructure and substantial surgical procedure volumes. The region exhibits high demand for hemostatic agents stemming from the increasing prevalence of chronic conditions and an aging population requiring various surgical interventions, including orthopedic and cardiovascular procedures. Additionally, the strong presence of key market players, coupled with robust research and development activities, fosters continuous innovation in hemostatic product development. Regulatory support from bodies such as the U. S. Food and Drug Administration, which facilitates new product approvals, further contributes to North America's leading position, ensuring the widespread adoption of effective bleeding control solutions.

Recent Developments

• In April 2025, Baxter International Inc. introduced its Hemopatch Sealing Hemostat with room temperature storage in Europe, representing a notable product evolution in the global hemostats market. This advanced collagen-based pad is designed for rapid and convenient application during both open and minimally invasive surgical procedures. The updated formulation eliminates the need for refrigeration, which significantly improves logistical efficiency and immediate accessibility in operating rooms. This innovation stemmed from ongoing collaboration between the company and surgeons, addressing critical clinical needs and enhancing patient care by providing a ready-to-use solution for controlling bleeding and preventing leakage.

• In September 2024, Medcura, Inc., a company specializing in hemostasis solutions, received a 2024/2025 Best Technology in Spine Award for its LifeGel Absorbable Hemostatic Gel. This recognition highlights significant breakthrough research in biopolymer-based hemostatic technology aimed at controlling surgical bleeding, particularly within spine procedures. The product is notable for being the first and only surgical hemostatic agent to receive an FDA Breakthrough Device Designation, signifying its potential to offer a more effective treatment for life-threatening or irreversibly debilitating conditions. The award was formally accepted at the North American Spine Society (NASS) meeting.

• In February 2024, Teleflex announced the release of its Hemostatic Matrix with Rapid Thrombus Formation Technology. This new product is designed for effective bleeding control across various surgical procedures within the global hemostats market. The introduction of this technology addresses the need for solutions that can achieve hemostasis efficiently. This launch expands Teleflex’s portfolio of advanced surgical tools, aiming to support medical professionals in managing complex bleeding situations and improving patient outcomes in diverse clinical settings.

• In 2024, Cresilon received FDA approval for its innovative hemostatic agent, TRAUMAGEL, with a national rollout planned for 2025. This plant-based gel is designed to swiftly manage moderate to severe bleeding, primarily targeting emergency medical services, first responders, and trauma centers. TRAUMAGEL forms an immediate mechanical barrier upon application, leveraging a proprietary polysaccharide blend to bond with wounds and accelerate bleeding control without requiring manual pressure. This product represents a substantial advancement in hemorrhage management, providing an efficient alternative to traditional methods in critical trauma care scenarios.

Key Market Players

• Johnson & Johnson
• Baxter International Inc.
• Pfizer Inc
• B Braun Medical Inc
• Becton, Dickinson, and Company
• Teleflex Incorporated
• Medtronic Plc
• Hemostasis, LLC
• Stryker Corporation
• Integra LifeSciences Corporation

Report Scope:

In this report, the Global Hemostats Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Hemostats Market, By Type:

o   Thrombin-based Hemostats

o   Oxidized Regenerated Cellulose-based Hemostats

o   Combination Hemostats

o   Gelatin-based Hemostats

o   Collagen-based Hemostats

o   Other Hemostats

• Hemostats Market, By Formulation:

o   Matrix & Gel Hemostats

o   Sheet & Pad Hemostats

o   Sponge Hemostats

o   Powder Hemostats

• Hemostats Market, By Application:

o   Orthopedic Surgery

o   General Surgery

o   Neurological Surgery

o   Cardiovascular Surgery

o   Reconstructive Surgery

o   Gynecological Surgery

o   Other Surgical Applications

• Hemostats Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hemostats Market.

Available Customizations:

Global Hemostats Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Hemostats Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]